07 February 2017: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, was informed on 7 February 2017 that, on the same day, Michael Hunt, the Company’s Chief Financial Officer, acquired 250,000 ordinary shares of 1p each (“Ordinary Shares”) at a price of 2.64p per share.

Read more…

Back